Former AXA subsidiary Bluefin slapped with £4m FCA fine

Michele Maatouk WebFG News | 06 Dec, 2017 11:39 | | |

FCA

The Financial Conduct Authority has fined insurance broker Bluefin - a former AXA subsidiary - £4m for misleading customers.

The regulator said Bluefin had inadequate systems and controls and failed to provide information to its customers about independence in a way that was "clear, fair and not misleading".

Between 9 March 2011 and 31 December 2014, Bluefin held itself out to be "truly independent" in the advice it provided and the insurers it recommended to customers. However, the FCA found that it failed to implement adequate systems and controls to manage the conflict that arose from its ownership.

"Bluefin’s independence was compromised by its culture which promoted business strategies, including a policy which focused on increasing the business placed with its parent company, over treating customers fairly," it said.

Brokers at Bluefin, which was sold by AXA on 31 December 2016, did not disclose this policy, meaning that customers risked being misled into believing they were dealing with a broker who would conduct an unbiased search of the market.

Mark Steward, executive director of enforcement and market oversight, said: "Insurance brokers must promote a culture in which they act in their customers’ best interests and provide them with the information they need to make an informed decision. This is central to the relationship between the industry and its customers.

"It is also unacceptable that firms hold themselves out as independent when they are not."

Bluefin agreed to settle at an early stage of the investigation and received a 30% discount on the fine.

More news

17:53 London close: Forties failure lifts FTSE as inflation spikes

London stocks extended their gains on Tuesday as supply disruptions boosted the energy sector and investors mulled higher than expected UK inflation figures.

17:33 US open: Boeing, 3M push Dow Industrials to fresh record-high

Wall Street's main indices are again heading higher on Tuesday as the Federal Reserve kicks off its two-day rate-setting meeting and several positive updates from corporate heavyweights such as Boeing and 3M.

17:34 EasyJet acquisition of Air Berlin assets approved by European Commission

UK budget airline easyJet cleared a major regulatory hurdle on Tuesday as its proposed acquisition of airport slots and aircraft from Air Berlin was approved by the European Commission.

17:49 Facebook to overhaul its tax structure worldwide

Facebook will move its global tax and revenue base from Ireland and begin booking advertising locally in every country where it operates.

16:51 GSK given green light for Churg-Strauss syndrome treatment

GlaxoSmithKline has been given approval by the US drug regulator for a first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.

16:44 Trump accuses Democrats of plot after sexual harassment claims

US President Donald Trump has claimed Democrats are behind a series of sexual harassment claims made against him this week.

16:41 Trump vows to send American astronauts to the moon

Donald Trump, the President of the United states signed the Space Policy Directive 1 to send astronauts to the moon again and to Mars for the first time in history.

16:33 Goldman Sachs keeps Barclays and Lloyds at 'sell'

Goldman Sachs reiterated its 'sell' recommendation on shares of Lloyds and Barclays, placing both stocks on its list of 'UK Sell Ideas' for 2018.

16:27 EU Brexit negotiator says David Davis comments 'undermine trust'

Brexit secretary David Davis’ claim that the deal agreed by the UK and European Union last week is not binding has been branded “unacceptable” by bloc negotiator Guy Verhofstadt, who added that it “undermines trust” between the two teams.

16:23 GlaxoSmithKline upbeat on 'promising' data from Dreamm-1 blood cancer study

GlaxoSmithKline has presented promising new data from the dose expansion phase of the Dreamm-1 study of GSK2857916, an anti-B-cell maturation antigen (BCMA) antibody-drug conjugate to treat blood cancer.